Addressing Cancer Care Equity With Social Needs Screening for Leukemia

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This intervention study screens adults with various leukemias for social needs and introduces oncology social work early in care. It aims to assess feasibility, acceptability, and effects on financial burden, unmet social needs, psychosocial support, and quality of life, compared with usual care. The program, ACCESS-Leukemia, builds on prior SDOH screening work in cancer settings and focuses on translating screening into timely support. The study is conducted at Massachusetts General Hospital and involves multilingual capabilities to include English and Spanish speakers. Outcomes of interest include changes in social needs and patient-reported quality of life.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1\. Adult patients ≥18 years who are newly referred to the outpatient Adult Leukemia Treatment Program with the following diagnoses:

1. Acute myeloid leukemia (AML)
2. Acute lymphoblastic leukemia (ALL)
3. Intermediate or high-risk myelodysplastic syndrome (MDS), as defined by the revised International Prognostic Scoring System (IPSS-R) and/or IPSS-molecular (IPSS-M)
4. Intermediate or high-risk chronic myelomonocytic leukemia (CMML) by the CMML-specific prognostic scoring system (CPSS-Mol)
5. Patients with lower risk MDS or CMML may also be included if baseline peripheral blood labs indicate anticipated transfusion dependence, defined as needing ≥2 units of red blood cells every 28 days
6. Patients with lower risk MDS or CMML may also be included if anticipated visits with the leukemia clinic exceed once per month by primary oncologist

2\. Ability to complete surveys in English, Spanish, or with assistance of an interpreter.

Exclusion Criteria:

1. Adults unable to consent due to lack of capacity based on their leukemia clinician assessment.
2. Individuals who are not yet adults (infants, children, teenagers).

Where it's running

• Mass General Brigham Cancer Institute
  Boston, Massachusetts, United States Recruiting

Study contacts

• Principal investigator: Michelle H Lee, MD — Mass General Brigham Cancer Institute
• Study coordinator: Michelle H Lee, MD
• Email: MLEE37@mgb.org
• Phone: 617-882-6060

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Assessing frailty to improve treatment for older patients with blood cancers

  This study is testing if checking how frail older patients with blood cancers are can help doctors choose better treatments for them.

  Recruiting Abramson Cancer Center at Penn Medicine · Philadelphia, Pennsylvania · NCT03680677

• Tailored exercise program to improve quality of life for adults with hematologic cancers

  This pilot trial tests a personalized 16-week exercise program to see if it’s feasible and helpful for adults with acute myeloid leukemia, lymphoma, or multiple myeloma after first-line treatment.

  Recruiting Gruppo Italiano Malattie EMatologiche dell'Adulto · Roma, Rm and 2 other locations · NCT07912684

• Characterization of CD180 Protein Expression in Myeloid Blood C cancers

  This study tests how CD180 is presented on myeloid cancer cells and normal stem cells using existing patient samples from AML cases to see if it could help with diagnosis or monitoring.

  Recruiting University Hospital, Strasbourg, France · Strasbourg · NCT07895901

• Personalized AML: Find biomarkers to predict response to venetoclax

  This study tests whether single-cell analyses can help group AML patients by biology and find biomarkers that predict who will respond to venetoclax.

  Recruiting Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · Milan · NCT07874100

• Low-dose Liposomal Amphotericin B for preventing fungal infections in adults with blood cancers and prolonged neutropenia

  This study tests whether giving a daily 50 mg dose of liposomal amphotericin B can help prevent invasive fungal infections in adults with blood cancers who have prolonged low white blood cell counts.

  Recruiting Haikou Affiliated Hospital of Central South University Xiangya School of Medicine · Hainan, Hainan · NCT07763054

• MAX-40279 with Venetoclax and Azacitidine for unfit newly diagnosed AML

  This study tests MAX-40279 added to venetoclax and azacitidine in older or unfit adults newly diagnosed with AML to see if it is safe and shows activity.

  Recruiting Phase 2 Maxinovel Pty., Ltd. · Tianjin · NCT07743112

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.